Studying a new drug combo for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a new drug (BL-B01D1) given alone or with another drug that helps the immune system fight cancer (called a PD-1 inhibitor). It is for people with newly diagnosed, locally advanced nasopharyngeal cancer. The goal is to see if this combination can shrink or control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been newly diagnosed with a type of nasopharyngeal cancer called non-keratinizing carcinoma.
- Your cancer is locally advanced (stage T4N1M0 or T1-4N2-3M0).
- You have not had any prior treatment for this cancer.
- You are in good enough health to care for yourself and do light activities (ECOG 0 or 1).
- Your heart and major organs are working well enough (heart pumping function at least 50%, no serious heart disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug (BL-B01D1) to an immunotherapy maintenance treatment can help keep nasopharyngeal cancer from growing after initial chemotherapy. It aims to improve how long patients live without the cancer progressing.
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests whether a special analysis of blood markers and imaging scans can help doctors choose the best combination of chemotherapy and radiation for nasopharyngeal cancer. The goal is to improve outcomes by tailoring treatment to each patient's specific cancer characteristics.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.